ALDH1A1 and ALDH1A3 isoforms are both reported to be predictive biomarkers of poor clinical outcome in BC (Liu et al., 2014; Marcato et al., 2011), and we found them to be the most highly increased among 18 ALDH isoforms detected in metastatic patient-derived ALDH+ BC cells. Here, ALDH1A1 is linked to breast cancer.